2012考研英语阅读真题:考研英语(二)第3篇
In 2010. a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades——by 2005 some 20% of human genes were patented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organization (BIO),a trade group, assured members that this was just a "preliminary step" in a longer battle.
On July 29th they were relieved, at least temporarily. A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.
But as companies continue their attempts at personalized medicine, the courts will remain rather busy. The Myriad case itself is probably not over. Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case, arguing that an isolated DNA molecule "is no less a product of nature... than are cotton fibres that have been separated from cotton seeds." Despite the appeals court's decision, big questions remain unanswered. For example, it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it. The case may yet reach the Supreme Court。
As the industry advances, however, other suits may have an even greater impact. Companies are unlikely to file many more patents for human DNA molecules——most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug's efficacy. Companies are eager to win patents for "connecting the dots", explains Hans Sauer, a lawyer for the BIO。
Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents. Each meeting was packed。
2010年,一个联邦法官对美国生物科技行业产生了巨大影响。各家公司早就获得了单个DNA的专利,2005年大约有20%的人类基因被授予专利。但2010年3月,一位法官判决基因是不能授予专利的。执行高管们一下燥热不安。生物科技行业组织(BIO)是贸易组织,该组织认为这个判决是长期斗争的一个前奏。
7月29日,他们放松了一下,至少暂时放松了一会儿。联邦上诉法院推翻了前面的判决,认为Myriad Genetics的确可以持有的两个帮助预测女性乳腺癌的基因专利。位于犹他州的Myriad首席执行官说,这个判决对于公司和患者都是一种赐福。
但是,正当公司继续试图个性化医疗的时候,法院将继续忙于此事。Myriad案本身可能不会结束。批评人士有三个理由反对基因专利:基因是自然的产物,所以不可以给予专利;基因专利不会鼓励创新反而会打压创新;基因垄断企业比如Myriad会限制其它公司进行基因测试。越来越多的人似乎同意这种说法。去年,联邦特派组敦促基因检测专利改革。十月,司法部在Myriad案中发表声明,单个DNA分子和从棉籽上分离出来的棉纤维一样,都是自然的产物。尽管上诉法院作出这样的判决,但是重要的问题仍然没有得到回答。比如说,基因组序列是否违背了其中单个基因专利仍无定论,这个问题可能要到最高法院裁决。
但是,随着该行业的发展,其它的案例可能会有更大的影响力。公司不大可能申请到更多的人类DNA专利——有些已经被其它公司申请或者处于共同申请的领域。公司正在研究基因是如何相互作用的,基因的相关性可以用来判断疾病的起因或者预测药物的功效。BIO的律师Hans Sauer解释道,公司渴望获得专利来以便归纳推理得出结论。
他们是否成功可能要由Mayo Clinic带来的这个案件的诉讼情况决定。最高法院将在下一轮审理此案。生物科技行业组织(BIO)最近开会讨论聘用律师来处理摇摆不定的专利案。每个会议都人满为患。
重点单词
blessing['blesiŋ]n. 祝福,祷告
molecule['mɔlikju:l]n. 分子
unclearadj. 不清楚的;不易了解的
temporarily['tempərerili]adv. 暂时地,临时地
innovation[.inəu'veiʃən]n. 创新,革新
determined[di'tə:mind]adj. 坚毅的,下定决心的
genome['dʒi:nəum]n. [生]基因组;[生]染色体组
separated['sepəreitid]adj. 分居;分开的;不在一起生活的 v. 分开;隔开
gene[dʒi:n]n. 基因
prior['praiə]adj. 优先的,更重要的,在前的
小编说:时间从来都是很快的流逝,尤其是对于忙碌的人,今天的你如果感觉天黑来的很快,那么请庆幸你的忙碌,这样的忙碌带来不仅是成绩的提升,还同时在提升你的个人能力,让你在将来比其他人更快的步入财务相对自由的状态,高学历不仅是成绩的印证,更是能力的代表!!抓住最后改变机会,就从你加入冲刺密训营开始!2018年考研报名流程 冲刺密训 把握最后50天 全面提分
冲刺阶段提升需注意 | ||
重点关注 | 黄金十月 精准择校 | 读懂院校招简,复习不跑偏 |
考研报名流程注意事项全解析 | 考研名师带着走 视频免费666 | |
2018考研知识“冲刺提升”大作战 | 不得不知的考研大纲解读 | 2018年考研报名注意事项问答专栏 |
2022考研初复试已经接近尾声,考研学子全面进入2023届备考,跨考为23考研的考生准备了10大课包全程准备、全年复习备考计划、目标院校专业辅导、全真复试模拟练习和全程针对性指导;2023考研的小伙伴针也已经开始择校和复习了,跨考考研畅学5.0版本全新升级,无论你在校在家都可以更自如的完成你的考研复习,暑假集训营带来了院校专业初步选择,明确方向;考研备考全年规划,核心知识点入门;个性化制定备考方案,助你赢在起跑线,早出发一点离成功就更近一点!
考研院校专业选择和考研复习计划 | |||
2023备考学习 | 2023线上线下随时学习 | 34所自划线院校考研复试分数线汇总 | |
2022考研复试最全信息整理 | 全国各招生院校考研复试分数线汇总 | ||
2023全日制封闭训练 | 全国各招生院校考研调剂信息汇总 | ||
2023考研先知 | 考研考试科目有哪些? | 如何正确看待考研分数线? | |
不同院校相同专业如何选择更适合自己的 | 从就业说考研如何择专业? | ||
手把手教你如何选专业? | 高校研究生教育各学科门类排行榜 |
相关推荐
跨考考研课程
班型 | 定向班型 | 开班时间 | 高定班 | 标准班 | 课程介绍 | 咨询 |
秋季集训 | 冲刺班 | 9.10-12.20 | 168000 | 24800起 | 小班面授+专业课1对1+专业课定向辅导+协议加强课程(高定班)+专属规划答疑(高定班)+精细化答疑+复试资源(高定班)+复试课包(高定班)+复试指导(高定班)+复试班主任1v1服务(高定班)+复试面授密训(高定班)+复试1v1(高定班) | |
2023集训畅学 | 非定向(政英班/数政英班) | 每月20日 | 22800起(协议班) | 13800起 | 先行阶在线课程+基础阶在线课程+强化阶在线课程+真题阶在线课程+冲刺阶在线课程+专业课针对性一对一课程+班主任全程督学服务+全程规划体系+全程测试体系+全程精细化答疑+择校择专业能力定位体系+全年关键环节指导体系+初试加强课+初试专属服务+复试全科标准班服务 |